MJ - GW Pharmaceuticals: The One 'Cannabis Stock' Everyone Should Own
- GW Pharmaceuticals Plc is a pharma company and a global leader in developing cannabinoid-based medicines.
- Its multiple sclerosis drug nabiximols (brand name Sativex) was the first natural cannabis plant derivative to gain FDA approval.
- 2020’s US election night was a potential tipping point for easing CBD regulations and legalizing cannabis.
- Amid CBD’s astronomical growth projections, GW Pharmaceuticals continues to see significant returns, revenue growth, and bullish projections.
For further details see:
GW Pharmaceuticals: The One 'Cannabis Stock' Everyone Should Own